Previous close | 0.7650 |
Open | 0.7773 |
Bid | 0.7351 x 300 |
Ask | 0.8094 x 300 |
Day's range | 0.7378 - 0.7829 |
52-week range | 0.7340 - 1.9100 |
Volume | |
Avg. volume | 230,752 |
Market cap | 29.53M |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Dev
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapi
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website